In the harvest season of October, the project data meeting of the phase III study, “a randomized, double-blind, parallel controlled trial comparing the efficacy and safety of recombinant anti-VEGF humanized monoclonal antibody injection (SIBP04) and bevacizumab injection (avittin ®) in combination with paclitaxel and carboplatin in patients with advanced, metastatic or relapsed non-squamous and non-small cell lung cancer”, was successfully held at 9 am In September 25, 2021 at the foot of the beautiful Jinshanling Great Wall. Since the project was approved by the group leader on October 17, 2019, H&J had suffered from the outbreak of the epidemic and the ravage of the flood. However, through the persistence of staff efforts, the project schedule has not been affected, and even was finished six months ahead of the schedule. To be honest, it is a great achievement. To memorize this moment and keep forward in future, we sincerely invited Dr.Fenglian Qu, Shunling Jiang, Shuting li and five site representatives (Sheng Yang, Guolei Wang, Minghong Bi, Yinghua Ji, and Qingshan Li) to witness our oath: we can do it and we can do better!

Presided over by General Manager Zhou Xiaodong, the conference was broadcast live both online and offline. Dr.Shi, the leading Principal investigator, fully affirmed the process and results of clinical trial in strict compliance with GCP requirements. At this meeting, Director Yanni Wang of the data Department and Deputy Director Lifeng Jin of the statistics Department made a comprehensive report on the overall data situation of the project. For some site special cases, experts spoke freely and discussed the problems extensively and deeply, and Dr.Shi led expert team to draw final conclusions after the discussion. After the meeting, the experts visited the Jinshanling Great Wall to enjoy the beauty and natural scenery of the Great Wall. The meeting was successfully ended with the joint efforts of colleagues from various departments.